Sandborn WJ - Search Results

1

Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.

Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. Singh S, et al. Among authors: sandborn wj. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002-1014. doi: 10.1016/S2468-1253(21)00312-5. Epub 2021 Oct 22. Lancet Gastroenterol Hepatol. 2021. PMID: 34688373 Free PMC article.

2

An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease.

Sandborn WJ, Van O EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. Sandborn WJ, et al. Gastroenterology. 1995 Dec;109(6):1808-17. doi: 10.1016/0016-5085(95)90747-5. Gastroenterology. 1995. PMID: 7498645 Clinical Trial.

3

Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine.

Sandborn WJ, Tremaine WJ, Lawson GM. Sandborn WJ, et al. Am J Gastroenterol. 1996 Jan;91(1):37-43. Am J Gastroenterol. 1996. PMID: 8561141

4

A new syndrome of Crohn's disease and pachydermoperiostosis in a family.

Compton RF, Sandborn WJ, Yang H, Lindor NM, Tremaine WJ, Davis MD, Khalil AA, Tountas NA, Tyan DB, Landers CJ, Taylor KD, Viggiano TR, Matteson EL, Schroeter AL, Plevy SE, Cominelli F, Targan SR, Rotter JI. Compton RF, et al. Among authors: sandborn wj. Gastroenterology. 1997 Jan;112(1):241-9. doi: 10.1016/s0016-5085(97)70241-5. Gastroenterology. 1997. PMID: 8978365

5

Azathioprine: state of the art in inflammatory bowel disease.

Sandborn WJ. Sandborn WJ. Scand J Gastroenterol Suppl. 1998;225:92-9. doi: 10.1080/003655298750027290. Scand J Gastroenterol Suppl. 1998. PMID: 9515759 Review.

6

Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.

Egan LJ, Sandborn WJ, Tremaine WJ. Egan LJ, et al. Among authors: sandborn wj. Am J Gastroenterol. 1998 Mar;93(3):442-8. doi: 10.1111/j.1572-0241.1998.00442.x. Am J Gastroenterol. 1998. PMID: 9517654 Clinical Trial.

7

Is antibody testing for inflammatory bowel disease clinically useful?

Panaccione R, Sandborn WJ. Panaccione R, et al. Among authors: sandborn wj. Gastroenterology. 1999 Apr;116(4):1001-2; discussion 1002-3. doi: 10.1016/s0016-5085(99)70087-9. Gastroenterology. 1999. PMID: 10092326 No abstract available.

8

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort.

Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. Silverstein MD, et al. Among authors: sandborn wj. Gastroenterology. 1999 Jul;117(1):49-57. doi: 10.1016/s0016-5085(99)70549-4. Gastroenterology. 1999. PMID: 10381909

9

The appendix in ulcerative colitis: a not so innocent bystander.

Panaccione R, Sandborn WJ. Panaccione R, et al. Among authors: sandborn wj. Gastroenterology. 1999 Jul;117(1):272-3. doi: 10.1016/s0016-5085(99)70581-0. Gastroenterology. 1999. PMID: 10381940 No abstract available.

10

Mycophenolate mofetil for Crohn's disease?

Lowry PW, Sandborn WJ, Lipsky JJ. Lowry PW, et al. Among authors: sandborn wj. Lancet. 1999 Jul 3;354(9172):3-4. doi: 10.1016/S0140-6736(99)00152-X. Lancet. 1999. PMID: 10406354 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

947 results

Search Page